Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

ANN ARBOR, Mich., Feb. 04, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...

Sight Sciences (NASDAQ:SGHT – Get Free Report) had its target price dropped by analysts at Stifel Nicolaus from $6.00 to $5.00 in a research report issued to clients and investors on Thursday,Benzinga ...

Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and ...

The company's OMNI Surgical System has also shown promise in reducing intraocular pressure in patients with primary open-angle glaucoma. This article was generated with the support of AI and ...

In a challenging market environment, Sight Sciences , Inc. (NASDAQ:SGHT) stock has touched a 52-week low, with shares falling to $2.54. With a market capitalization of $130.44 million and an ...

2025 represents a “foundational building year” in which the company’s key growth driver will shift away from the legacy Omni surgical solution to treat glaucoma and to the TearCare dry eye ...

Standalone canaloplasty and trabeculotomy can deliver meaningfully reduced IOP in the long term and require fewer topical therapy agents.

Pseudoexfoliation glaucoma is linked with an increased risk of heart attack and stroke. Ophthalmologists must be careful to not confuse signs of pseudoexfoliation with pigmentary glaucoma.